Bifogade filer
240109 EXPRS2 Events Upcoming
Kurs
-0,84%
Likviditet
0,04 MSEK
Kalender
| Est. tid* | ||
| 2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2025-05-28 | - | Årsstämma |
| 2025-05-15 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-30 | - | Split EXPRS2 40:1 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2024-06-05 | - | Årsstämma |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-23 | - | Extra Bolagsstämma 2023 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-23 | - | Extra Bolagsstämma 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-07 | - | Bokslutskommuniké 2017 |
| 2017-11-30 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2017-05-31 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-19 | - | Extra Bolagsstämma 2017 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-08 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at either event, please contact us at info@expreS2ionbio.com.
13-16 January 2025 | PepTalk - Protein Science and Production Week
San Diego, California, USA
PepTalk is a leading conference focused on advancing biotherapeutic discovery and development. On 16 January at 11:30 AM PST, ExpreS2ion’s VP of R&D and Technology, Max Søegaard, will present a talk titled “Advancements in VLP Technology: From Pandemic Countermeasures to Broad-Spectrum Applications in Vaccine Development.” Additional details are available on the Peptalk website.
16 January 2025 | Institutional Investor Seminar
Copenhagen, Denmark
ExpreS2ion’s CEO, Bent Frandsen, will present at an Institutional Investor Seminar hosted by HC Andersen Capital. The presentation will focus on ES2B-C001, ExpreS2ion’s novel therapeutic breast cancer vaccine, which recently received Clinical Trial Application (CTA) approval from Austrian regulatory authorities for a Phase I clinical trial. Nordic institutional investors interested in attending are encouraged to contact HC Andersen Capital for participation details.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.